Test Code CDAU7 Drug Abuse Survey with Confirmation, Panel 9, Random, Urine
Reporting Name
Confirmed Drug Abuse Panel 9, UUseful For
Detecting drug abuse involving, amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
Performing Laboratory

Specimen Type
UrineOrdering Guidance
For situations where chain-of-custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order CDA7X / Drug Abuse Survey with Confirmation, Panel 9, Chain of Custody, Urine.
Additional Testing Requirements
If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine. For additional information, please refer to ADULT / Adulterants Survey, Urine.
Specimen Required
Supplies: Urine Container, 60 mL (T313)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. Submit 30 mL in 1 plastic bottle.
3. No preservative.
Additional Information:
1. No specimen substitutions.
2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.
3. Submitting less than 30 mL will compromise our ability to perform all necessary testing.
Specimen Minimum Volume
15 mL
Testing Algorithm
Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite) at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 7 days | |
Frozen | 14 days |
Reference Values
Negative
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 100 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Ethanol: 10 mg/dL
Methadone metabolite: 300 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Day(s) Performed
Monday through Saturday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80307
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CDAU7 | Confirmed Drug Abuse Panel 9, U | 87428-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
30909 | Alcohol | 34180-0 |
2573 | Amphetamines | 43983-6 |
2574 | Barbiturates | 70155-7 |
2575 | Benzodiazepines | 16195-0 |
21652 | Cocaine | 19359-9 |
4435 | Methadone metabolite | 16246-1 |
2577 | Opiates | 18390-5 |
2578 | Phencyclidine | 18392-1 |
2664 | Tetrahydrocannabinol | 19415-9 |
20672 | Chain of Custody | 77202-0 |
Clinical Reference
1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. Chapter 35. WB Saunders Co, 2011, pp 1109-1188
Method Description
The amphetamines, barbiturates, benzodiazepines, cocaine, methadone metabolite, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.
ADH
Ethyl alcohol + NAD+ -----------------> acetaldehyde + NADH + H+
Report Available
Same day/1 to 2 daysReject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. |
Method Name
CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
ETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
OPATU | Opiate Confirmation, U | Yes | No |
AMPHU | Amphetamines Confirmation, U | Yes | No |
BARBU | Barbiturates Confirmation, U | Yes | No |
COKEU | Cocaine and metabolite Conf, U | Yes | No |
ETOH | Ethanol, U | No | No |
MTDNU | Methadone Confirmation, U | Yes | No |
PCPU | Phencyclidine Confirmation, U | Yes | No |
THCU | Carboxy-THC Confirmation, U | Yes | No |
BNZU | Benzodiazepines Confirmation, U | Yes | No |